ADMA Biologics, Inc. (ADMA) AI Stock Analysis

ADMA Biologics, Inc., based in Ramsey, New Jersey, develops, manufactures, and distributes specialty plasma-derived biologics. Its commercial products include BIVIGAM and ASCENIV, both intravenous immune globulin therapies indicated for primary humoral immunodeficiency, as well as Nabi-HB for treatment following acute exposure to Hepatitis B. The company also advances pipeline therapies targeting S. pneumoniae infections. ADMA Biologics operates its own source plasma collection facilities to supply manufacturing and distributes its therapies through independent distributors, sales agents, specialty pharmacies, and alternate site providers.

Revenue expanded from $80.9M in FY2021 to $510.2M in FY2025, representing a 5-year revenue CAGR of 64.6%. Gross margin rose from 1.4% in FY2021 to 57.4% in FY2025, while operating margin improved from -72.1% to 37.5%. After reporting a net loss of -$71.6M in FY2021, the company achieved net income of $197.7M in FY2024 and $146.9M in FY2025. Operating cash flow totaled $50.4M in FY2025, down from $118.7M in FY2024. For the quarter ended June 30, 2026, revenue increased 2.0% year-over-year, while quarterly earnings grew 14.3% year-over-year.

As of June 30, 2026, ADMA Biologics held $136.0M in cash and short-term investments alongside total debt of $203.8M, resulting in net debt of $67.8M. The company reported shareholders' equity of $408.2M, a debt-to-equity ratio of 0.50, and a current ratio of 6.97. In FY2025, operating cash flow reached $50.4M and free cash flow stood at $27.8M. Capital deployment in FY2025 included $22.6M in capital expenditures and $31.9M directed toward share buybacks.

At $10.68, ADMA Biologics holds a market cap of $2.39B and an enterprise value of $2.24B. The stock trades at a trailing P/E of 15.3x and a forward P/E of 9.8x, both below the median of its US-listed Healthcare peers at 24.6x and 17.3x, respectively. Its EV/EBITDA of 9.6x is lower than the peer median of 12.0x, while its price-to-sales multiple of 4.7x is above the peer median of 4.1x. Over the past year, ADMA fell 26.6%, trailing the S&P 500 return of 16.8%, but gained 870.9% over five years versus 83.0% for the index.

Wall Street coverage includes 2 Strong Buy, 1 Buy, and 1 Hold ratings, with zero Sell or Strong Sell ratings. The mean price target of $17.00 implies an upside of 59.2% relative to the closing price of $10.68. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $535.3M and EPS of $0.80, representing 21.3% EPS growth. The company has beaten EPS expectations in 1 of the last 4 quarters, and its next earnings release is scheduled for November 4, 2026.

This page is an AI-written research summary of ADMA Biologics, Inc. (ADMA). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: ADMA income statement, ADMA balance sheet, ADMA key metrics, ADMA analyst forecast, ADMA chart. See the ADMA stock overview for the latest quote and news.